Acrivon therapeutics to host corporate r&d event to provide ap3 platform capabilities and clinical acr-368 and acr-2316 program updates

Event to be held via webcast on march 25, 2025 at 4:00 p.m. et to highlight differentiated drug discovery capabilities with its generative phosphoproteomics ap3 platform and program updates from the phase 2b study of acr-368 and phase 1 study of acr-2316 watertown, mass.

ACRV Ratings Summary

ACRV Quant Ranking